Chris Martin, ADC Therapeutics CEO
April 23, 2021 04:15 PM EDTUpdated 04:33 PM
FDA+

ADC Ther­a­peu­tics nabs its first ap­proval as FDA of­fers a quick OK for its DL­B­CL can­cer treat­ment

John Carroll

Editor & Founder

The FDA won’t be wait­ing around for the PDU­FA date for its lat­est OK on the can­cer front.

Reg­u­la­tors came through with an ac­cel­er­at­ed ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Take­da to pay $200M for rights to ane­mia drug from Keros

Janux soars on ear­ly prostate can­cer da­ta that could chal­lenge No­var­tis' Plu­vic­to

Roche teams up with Chica­go au­toim­mune biotech COUR Phar­ma­ceu­ti­cals

Rev­o­lu­tion sells $600M in shares on back of RAS in­hibitor port­fo­lio up­dates

Gilead makes an­oth­er ADC move, ink­ing up to $415M pact with Tubu­lis

Scott Got­tlieb says he’s against RFK Jr. for HHS: ‘It will cost lives in this coun­try’

A service from the Financial Times